The Lawyer Asia Pacific 150 is the only research report to provide a ranking of the top 100 independent local firms and top 50 global firms in the region. The report offers critical review of some of the fastest growing firms and their strategies, a country-by-country guide to leading legal advisers and legal services market trends, plus exclusive insight into the current business development opportunities in the Asia Pacific. Read more
This year, The Lawyer’s annual ranking of the largest UK law firms by turnover is available as an interactive, digital benchmarking tool. For the first time this will allow you to manipulate each data set against the metrics of your choice.
Willkie Farr & Gallagher has advised US dermatology company Stiefel Laboratories on its $3.6bn (£2.5bn) takeover by pharmaceutical giant GlaxoSmithKline (GSK)
Willkie Farr & Gallagher has advised US dermatology company Stiefel Laboratories on its $3.6bn (£2.5bn) takeover by pharmaceutical giant GlaxoSmithKline (GSK), in what is one of the biggest M&A transactions to hit the market in recent months.
Corporate partners William Grant and Greg Astrachan began advising Stiefel in 2006 following a beauty parade. They have since advised the company on a number of significant transactions including the $500m (£340m) investment by Blackstone in 2007 and its 2008 acquisition of Barrier Therapeutics.
Astrachan said: “There were three big M&A deals announced last Monday. My hope is that it’s a bellwether of future activity.” GSK will acquire the total share capital of Stiefel for $2.9bn (£1.9bn) and assume $400m (£300m) of net debt upon closing. A potential further $300m (£200m) cash payment is contingent on future performance.
Cleary Gottlieb Steen & Hamilton advised GSK. The team was led by New York-based corporate partner Benet O’Reilly, assisted by teams across antitrust, employee benefits, environmental, international diligence, IP, international regulatory, real estate and tax based in Brussels, New York and Washington DC.